Skip to main content
. 2019 Nov 14;4(22):e130516. doi: 10.1172/jci.insight.130516

Figure 1. Genome-wide siRNA screening to identify the therapeutic candidate target for ciliopathies.

Figure 1

(A) Experimental design of genome-wide siRNA screening. (B) AXIN2 qPCR was performed as the secondary validation. The same cell line used in the primary screen was transfected with siRNA targeting the 29 hits identified from the primary screening. Compared with the control-siRNA, relative expression level of AXIN2 from triplicated experiments is presented in the box-and-whiskers plot (Tukey’s post hoc test). Asterisks denote the genes that reduce AXIN2 expression significantly (P < 0.05; 2-tailed Student’s t test). (C) Chart of the results from primary screening, secondary validation, and in vivo CE assays.